DMH1: Selective BMP Type I Receptor (ALK2) Inhibitor for Precision Cell Signaling Control

Executive Summary: DMH1 (SKU B3686, APExBIO) is a potent and selective small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors, with an IC₅₀ of 107.9 nM for ALK2 and <0.5 μM for ALK2/ALK3 in cellular assays (APExBIO DMH1). It exhibits high specificity, sparing VEGF, KDR, ALK5, AMPK, and PDGFRβ signaling, and does not impact p38/MAP kinase or Activin A-induced Smad2 activation (GDC-0349 review). In non-small cell lung cancer (NSCLC) models, DMH1 suppresses tumor growth by inhibiting Smad1/5/8 phosphorylation and Id gene expression (Yang et al., 2025). Its solid form is insoluble in water/ethanol but dissolves in DMSO at ≥9.51 mg/mL, with storage at -20°C recommended. DMH1 enables reproducible, targeted BMP pathway modulation in both cancer and organoid systems, supporting high-throughput and translational research applications (Influenza-A-Virus-Fragment review).

Biological Rationale

BMP signaling regulates cellular differentiation, proliferation, and survival in multiple tissues. Aberrations in BMP pathways contribute to tumorigenesis, especially in non-small cell lung cancer (NSCLC), and disrupt organoid homeostasis (Yang et al., 2025). Targeted inhibition of BMP type I receptors (notably ALK2 and ALK3) enables mechanistic dissection of these processes, facilitating both disease modeling and therapeutic interrogation. DMH1, as a dorsomorphin analog, provides a high-specificity chemical tool for selective BMP inhibition without off-target effects on VEGF or related kinases. This selectivity is essential in organoid and cancer research where pathway-specific perturbation informs lineage commitment, self-renewal, and cell fate modulation (ALK-1.com review).

Mechanism of Action of DMH1

DMH1 selectively binds to the ATP-binding pocket of BMP type I receptors, with greatest affinity for ALK2 (IC₅₀ = 107.9 nM) and ALK3 (<0.5 μM in cells). This blocks phosphorylation of downstream Smad1/5/8 proteins, attenuating canonical BMP signaling. DMH1 does not inhibit VEGF receptor (KDR), ALK5, AMPK, PDGFRβ, or p38/MAP kinase pathways at relevant concentrations, thus minimizing non-specific effects. In cellular systems, DMH1 suppresses BMP-stimulated Id1, Id2, and Id3 gene expression and inhibits cell migration, invasion, and proliferation, while promoting programmed cell death in NSCLC lines. In organoid models, DMH1 shifts the balance between stem cell self-renewal and directed differentiation by modulating BMP-dependent niche signals (Product page).

Evidence & Benchmarks

• DMH1 inhibits ALK2 with an IC₅₀ of 107.9 nM and ALK2/ALK3 signaling in cells at <0.5 μM (APExBIO).
• No inhibitory effect on VEGF/KDR, ALK5, AMPK, or PDGFRβ at up to 10 μM, confirmed by kinase selectivity profiling (Difamilast Molecules).
• Significant inhibition of Smad1/5/8 phosphorylation observed in NSCLC and organoid models after 1–6 h exposure to 1 μM DMH1 (Yang et al., 2025).
• Reduces Id1, Id2, and Id3 gene expression by >50% in A549 lung cancer cells after 24 h at 1 μM (GDC-0349).
• Suppresses tumor growth by ~50% and increases tumor doubling time in A549 xenograft mouse models following daily intraperitoneal administration of 10 mg/kg for 21 days (Yang et al., 2025).
• Does not impair Activin A-induced Smad2 activation or p38 MAPK phosphorylation at concentrations up to 5 μM (Influenza-A-Virus-Fragment).
• Enables controlled, reversible shifts in human organoid self-renewal versus differentiation without artificial gradients (Yang et al., 2025).

Applications, Limits & Misconceptions

DMH1 is validated for dissecting BMP signaling in cancer, stem cell, and organoid studies. Its primary uses include:

• Selective inhibition of ALK2/ALK3-mediated Smad1/5/8 phosphorylation in NSCLC and other tumor cell lines.
• Modulation of self-renewal and differentiation dynamics in human and mouse intestinal organoids, as reported in tunable organoid systems (Yang et al., 2025).
• Validation of BMP pathway dependency in cell fate and lineage allocation studies.
• Use as a negative control for off-pathway effects due to its lack of impact on Activin A, VEGF, and unrelated kinases.

This article extends previous coverage by providing updated, quantitative in vivo and organoid benchmarks compared to DMH1: Selective BMP Type I Receptor (ALK2) Inhibitor for ... (which focuses on atomic mechanisms and translational tips) and clarifies application boundaries for NSCLC and organoid models, complementing the workflow guidance in DMH1 (SKU B3686): Reliable BMP Signaling Inhibition in Advanced Models.

Common Pitfalls or Misconceptions

• DMH1 is not a broad kinase inhibitor; it does not affect VEGF/KDR, ALK5, or AMPK at standard concentrations.
• It does not substitute for TGF-β/Smad2/3 pathway inhibitors; Activin A-induced signaling is unaffected.
• DMH1 is insoluble in water and ethanol; DMSO is required for stock preparation (≥9.51 mg/mL at 37°C with ultrasonication).
• Long-term DMSO solutions are unstable; prepare fresh or store at -20°C for short-term use only.
• Off-target cytotoxicity is rare at ≤5 μM in most cell-based models, but titration is advised for non-cancerous tissues.

Workflow Integration & Parameters

For DMH1 (B3686, APExBIO), reconstitute in DMSO to ≥9.51 mg/mL, warming to 37°C and applying ultrasonic shaking for optimal solubility. Store aliquots at -20°C; use within one month for best results. For cell-based assays, typical working concentrations are 0.1–2 μM, with exposure times from 1–48 hours depending on endpoint. For in vivo studies, daily intraperitoneal dosing of 10 mg/kg in appropriate vehicles is standard for xenograft models. In organoid protocols, DMH1 supports reversible modulation of stemness and differentiation without the need for exogenous spatial gradients, enabling high-throughput screening and mechanistic studies (Yang et al., 2025). For detailed guidance, refer to Precision BMP Signaling Modulation: Strategic Insights for Organoid Engineering, which provides scenario-driven protocols and strategic comparisons.

Conclusion & Outlook

DMH1 offers robust, selective BMP type I receptor inhibition for research in cancer biology and organoid modeling. Its specificity for ALK2/ALK3 enables precise modulation of cellular signaling with minimal off-target effects, advancing reproducibility in both high-throughput and translational research. The availability of DMH1 as a validated tool from APExBIO (see product page) supports scalable, mechanistic studies in both established and emerging cellular models. Future directions include expanded benchmarking across tissue types, optimization of dosing regimens, and integration with multiplexed pathway modulators to further dissect niche-dependent cell fate mechanisms (Yang et al., 2025).